ITRM950763A0 - - Google Patents

Info

Publication number
ITRM950763A0
ITRM950763A0 ITRM950763A ITRM950763A ITRM950763A0 IT RM950763 A0 ITRM950763 A0 IT RM950763A0 IT RM950763 A ITRM950763 A IT RM950763A IT RM950763 A ITRM950763 A IT RM950763A IT RM950763 A0 ITRM950763 A0 IT RM950763A0
Authority
IT
Italy
Application number
ITRM950763A
Other languages
Italian (it)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10764811&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ITRM950763(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of ITRM950763A0 publication Critical patent/ITRM950763A0/it
Publication of ITRM950763A1 publication Critical patent/ITRM950763A1/it
Application granted granted Critical
Publication of IT1282353B1 publication Critical patent/IT1282353B1/it

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Cosmetics (AREA)
  • Dental Preparations (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IT95RM000763A 1994-11-22 1995-11-20 Composizione farmaceutica, in particolare liquida, per sommanistrazione orale di ondansetron e metodi per la sua produzione IT1282353B1 (it)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB9423588A GB9423588D0 (en) 1994-11-22 1994-11-22 Compositions

Publications (3)

Publication Number Publication Date
ITRM950763A0 true ITRM950763A0 (https=) 1995-11-20
ITRM950763A1 ITRM950763A1 (it) 1997-05-20
IT1282353B1 IT1282353B1 (it) 1998-03-20

Family

ID=10764811

Family Applications (1)

Application Number Title Priority Date Filing Date
IT95RM000763A IT1282353B1 (it) 1994-11-22 1995-11-20 Composizione farmaceutica, in particolare liquida, per sommanistrazione orale di ondansetron e metodi per la sua produzione

Country Status (32)

Country Link
US (1) US5854270A (https=)
EP (1) EP0792149B1 (https=)
JP (1) JP2965704B2 (https=)
KR (1) KR100292124B1 (https=)
CN (1) CN1108153C (https=)
AT (1) ATE196084T1 (https=)
AU (1) AU703932B2 (https=)
BE (1) BE1009458A5 (https=)
BR (1) BR9509807A (https=)
CA (1) CA2205546C (https=)
CY (1) CY2171B1 (https=)
CZ (1) CZ285187B6 (https=)
DE (1) DE69518767T2 (https=)
DK (1) DK0792149T3 (https=)
ES (1) ES2151083T3 (https=)
FI (1) FI119356B (https=)
FR (1) FR2727015B1 (https=)
GB (2) GB9423588D0 (https=)
GR (1) GR3034684T3 (https=)
HU (1) HU226947B1 (https=)
IE (1) IE950884A1 (https=)
IL (1) IL116083A (https=)
IT (1) IT1282353B1 (https=)
NO (1) NO306892B1 (https=)
NZ (1) NZ297879A (https=)
PL (1) PL181522B1 (https=)
PT (1) PT792149E (https=)
RU (1) RU2145853C1 (https=)
SI (1) SI0792149T1 (https=)
TW (1) TW413634B (https=)
WO (1) WO1996015786A2 (https=)
ZA (1) ZA959820B (https=)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2162561B1 (es) * 1999-06-28 2002-07-16 Boehringer Ingelheim Espana Composicion farmaceutica de metamizol oral, liquida, transparente, estable y de sabor aceptable.
US6473876B1 (en) 1999-06-29 2002-10-29 Sony Corporation Method and apparatus for encoding of bitstreams using rotation
AU6934400A (en) * 1999-08-25 2001-03-19 Barrett R. Cooper Compositions and methods for treating opiate intolerance
RU2162695C1 (ru) * 2000-07-14 2001-02-10 ООО с иностранными инвестициями "Редди-Биомед лимитед" Способ получения ондансетрона гидрохлорида дигидрата, субстанция и фармацевтический препарат
EP1339707A2 (en) * 2000-10-30 2003-09-03 Teva Pharmaceutical Industries Ltd. Novel crystal and solvate forms of ondansetron hydrochloride and processes for their preparation
US20020115707A1 (en) * 2001-01-11 2002-08-22 Rami Lidor-Hadas Process for preparing pure ondansetron hydrochloride dihydrate
CA2480826C (fr) 2002-04-09 2012-02-07 Flamel Technologies Formulation pharmaceutique orale sous forme de suspension aqueuse de microcapsules permettant la liberation modifiee de principe(s) actif(s)
PT1499623E (pt) * 2002-04-29 2007-08-10 Teva Gyogyszergyar Zartkoeruee ''processo papa a preparação de 1, 2, 3, 9-tetra-hidro-9-metil-3- [(2-metil-1h-imidazol-1-il) metil] -4h-carbazol-4-ona''
MXPA04010845A (es) * 2002-04-30 2005-01-25 Biogal Gyogyszergyar Formas cristalinas novedosas de ondansetron, procesos para su preparacion, composiciones farmaceuticas que contienen las formas novedosas y metodos para tratar las nauseas utilizando las mismas.
US20050131045A1 (en) * 2002-04-30 2005-06-16 Judith Aronhime Novel crystal forms of ondansetron, processes for their preparation, pharmaceutical, compositions containing the novel forms and methods for treating nausea using them
DE10393729T5 (de) * 2002-11-15 2005-10-13 Helsinn Healthcare S.A. Verfahren zur Behandlung von Emesis
JO2735B1 (en) * 2003-01-30 2013-09-15 هيلسين هيلث كير أس ايه. Liquid pharmaceutical formulations of palonosetron
US8598219B2 (en) 2003-01-30 2013-12-03 Helsinn Healthcare Sa Liquid pharmaceutical formulations of palonosetron
TWI355936B (en) * 2003-02-18 2012-01-11 Helsinn Healthcare Sa Uses of palonosetron hydrochloride
US7390503B1 (en) 2003-08-22 2008-06-24 Barr Laboratories, Inc. Ondansetron orally disintegrating tablets
US20060167072A1 (en) * 2004-01-30 2006-07-27 Helsinn Healthcare Sa Liquid pharmaceutical formulations of palonosetron
JP2006028028A (ja) * 2004-07-12 2006-02-02 Teikoku Medix Kk 経口医薬組成物
CN100423779C (zh) * 2006-09-27 2008-10-08 中国药科大学 一种以5－羟色胺3受体拮抗剂和h2受体拮抗剂为活性成分的药用组合物及其制药用途
EP2124556B1 (en) 2006-10-09 2014-09-03 Charleston Laboratories, Inc. Pharmaceutical compositions
ES2620672T3 (es) 2008-01-09 2017-06-29 Charleston Laboratories, Inc. Comprimidos de doble capa que comprenden oxicodona y prometazina
US20110201597A1 (en) 2008-03-27 2011-08-18 Chase Thomas N Method and composition for treating alzheimer-type dementia
WO2011006012A1 (en) 2009-07-08 2011-01-13 Charleston Laboratories Inc. Pharmaceutical compositions
MX345236B (es) * 2009-09-18 2017-01-23 Chase Pharmaceuticals Corp Metodo y composicion para tratar la demencia de tipo alzheimer.
US20110288115A1 (en) * 2010-05-24 2011-11-24 Avmedis Llc Treatment of vagally-mediated spectrum disorders
US20120302616A1 (en) * 2010-12-03 2012-11-29 Nikhilesh Singh Method of treatment of obsessive compulsive disorder with ondansetron
KR101058749B1 (ko) * 2010-12-29 2011-08-24 에스씨바이오팜 주식회사 네오헤스피리딘 디하이드로찰콘을 감미료로 사용하는 온단세트론 염산염 이수화물 함유 액상 조성물
EP4035668A1 (en) 2012-09-05 2022-08-03 Chase Pharmaceuticals Corporation Anticholinergic neuroprotective composition and methods
US10172833B2 (en) 2015-08-11 2019-01-08 Insys Development Company, Inc. Sublingual ondansetron spray
KR101635820B1 (ko) * 2015-10-30 2016-07-04 재단법인 통합의료진흥원 온단세트론 및 반하후박탕을 포함하는 항암치료 보조용 조성물
JP2019507181A (ja) 2016-03-04 2019-03-14 チャールストン ラボラトリーズ，インコーポレイテッド 医薬組成物
KR101721094B1 (ko) * 2016-09-09 2017-03-29 재단법인 통합의료진흥원 댕댕이나무 열매 추출물을 포함하는 오심 및 구토 치료 효과 증진용 조성물
KR102675602B1 (ko) * 2023-09-01 2024-06-14 (주)옥천당 항암제 투여시 유발되는 소화관 장애의 효과적 제어가 가능한 신규 조성물

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LU88268I2 (https=) * 1984-01-25 1994-02-03
DE201165T1 (de) * 1985-03-14 1989-04-20 Beecham Group P.L.C., Brentford Arzneimittel zur behandlung von emesis, anxietas und "irritable bowel syndrome".
GB8516083D0 (en) * 1985-06-25 1985-07-31 Glaxo Group Ltd Heterocyclic compounds
EP0450757A3 (en) * 1990-02-22 1993-09-15 Glaxo Group Limited Use of 5-hydroxytryptamine-antagonists in the treatment of mental disorders originating in childhood
ITMI922854A1 (it) * 1992-12-15 1994-06-15 Boehringer Ingelheim Italia Uso degli antagonisti dei recettori 5-ht3

Also Published As

Publication number Publication date
BE1009458A5 (fr) 1997-04-01
CZ285187B6 (cs) 1999-06-16
GB9423588D0 (en) 1995-01-11
HU226947B1 (en) 2010-03-29
FR2727015B1 (fr) 1997-08-22
DE69518767D1 (de) 2000-10-12
ES2151083T3 (es) 2000-12-16
ATE196084T1 (de) 2000-09-15
NO972324L (no) 1997-07-21
CN1171740A (zh) 1998-01-28
EP0792149B1 (en) 2000-09-06
CY2171B1 (en) 2002-08-23
PL320288A1 (en) 1997-09-15
TW413634B (en) 2000-12-01
NO306892B1 (no) 2000-01-10
IE950884A1 (en) 1996-05-29
PT792149E (pt) 2001-02-28
FI119356B (fi) 2008-10-31
JPH10508866A (ja) 1998-09-02
CA2205546A1 (en) 1996-05-30
KR970706815A (ko) 1997-12-01
CA2205546C (en) 2000-01-25
AU703932B2 (en) 1999-04-01
NZ297879A (en) 1998-12-23
GB2295317A (en) 1996-05-29
DE69518767T2 (de) 2001-05-31
CZ154897A3 (en) 1997-10-15
FR2727015A1 (fr) 1996-05-24
EP0792149A2 (en) 1997-09-03
GB9523666D0 (en) 1996-01-24
CN1108153C (zh) 2003-05-14
SI0792149T1 (en) 2001-02-28
KR100292124B1 (ko) 2001-07-12
ITRM950763A1 (it) 1997-05-20
DK0792149T3 (da) 2000-12-18
WO1996015786A2 (en) 1996-05-30
AU4313596A (en) 1996-06-17
HUT77944A (hu) 1998-12-28
GB2295317B (en) 1998-11-25
GR3034684T3 (en) 2001-01-31
MX9703734A (es) 1997-09-30
NO972324D0 (no) 1997-05-21
IT1282353B1 (it) 1998-03-20
PL181522B1 (en) 2001-08-31
IL116083A0 (en) 1996-01-31
HK1009590A1 (en) 1999-06-04
WO1996015786A3 (en) 1996-06-27
FI972168L (fi) 1997-05-21
RU2145853C1 (ru) 2000-02-27
IL116083A (en) 2000-09-28
FI972168A0 (fi) 1997-05-21
ZA959820B (en) 1996-07-29
BR9509807A (pt) 1997-10-21
US5854270A (en) 1998-12-29
JP2965704B2 (ja) 1999-10-18

Similar Documents

Publication Publication Date Title
TW278209B (https=)
DK105996A (https=)
EP0666525A3 (https=)
EP0669395A3 (https=)
ITRM950763A0 (https=)
EP0667627A3 (https=)
BY1704C1 (https=)
DK0685247T3 (https=)
ECSDI940182S (https=)
CU22450A3 (https=)
EP0662420A3 (https=)
ECSMU940033U (https=)
ECSDI940187S (https=)
DK40195A (https=)
EP0663383A3 (https=)
EP0666125A3 (https=)
CN3029189S (https=)
CN3029313S (https=)
CN3029327S (https=)
CN3029354S (https=)
CN3028520S (https=)
CN3026925S (https=)
CN3026487S (https=)
CN3028268S (https=)
CN3025919S (https=)

Legal Events

Date Code Title Description
0001 Granted